M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC), Metastatic Castration Sensitive Prostate Cancer (MCSPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04633252
Phase: Phase 1|Phase 2
Trial Summary: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetax – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:

Pin It on Pinterest